Matches in DBpedia 2014 for { ?s ?p 3-Methoxyphencyclidine (3-MeO-PCP) is a dissociative anesthetic drug with hallucinogenic and sedative effects that has been sold as a research chemical. It is around the same potency as phencyclidine, but has slightly different effects due to its altered binding profile at various targets, particularly being somewhat more potent as an NMDA antagonist while having around the same potency as a dopamine reuptake inhibitor.The corresponding 4-methoxy derivative 4-MeO-PCP is also known, but is around 10 times less potent by weight than the 3-methoxy isomer, making it around the same potency as ketamine.3-MeO-PCP hydrochloride is a white crystalline solid with a melting point of 204-205°C 3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter and 42 for the sigma1 receptorOn October 18, 2012 the ACMD released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-MeO-PCP.. }
Showing items 1 to 1 of
1
with 100 items per page.
- 3-MeO-PCP abstract "3-Methoxyphencyclidine (3-MeO-PCP) is a dissociative anesthetic drug with hallucinogenic and sedative effects that has been sold as a research chemical. It is around the same potency as phencyclidine, but has slightly different effects due to its altered binding profile at various targets, particularly being somewhat more potent as an NMDA antagonist while having around the same potency as a dopamine reuptake inhibitor.The corresponding 4-methoxy derivative 4-MeO-PCP is also known, but is around 10 times less potent by weight than the 3-methoxy isomer, making it around the same potency as ketamine.3-MeO-PCP hydrochloride is a white crystalline solid with a melting point of 204-205°C 3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter and 42 for the sigma1 receptorOn October 18, 2012 the ACMD released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-MeO-PCP.".